跳至主要内容
临床试验/JPRN-UMIN000015100
JPRN-UMIN000015100已完成未知

Contemporary Management and Prognosis in Japanese peripheral artery disease patients with endovascular treatment - TOMAcode Registry

Tokyo Medical University Ibaraki Medical Center0 个研究点目标入组 2,000 人开始时间: 2014年9月9日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
2,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
10years-old 至 100years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.patients with endovascular treatment for the aneurysm 2.inappro@riate patients determined from study director

研究者

相似试验

已完成
不适用
Current Status of Nutritional Practice In Japan: A Multicenter Observational StudyPatients who receive mechanical ventilation for at least 24 hours and are in the ICU for longer than 72 hours
JPRN-UMIN000016871Kochi Medical School360
招募中
Unknown
Illustration of the Management and Prognosis of Japanese Patients with Cardiac Sarcoidosis by Multimodality Imaging and Genetic Analysis
JPRN-UMIN000053948Juntendo University550
未知
1 期
A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Patients With Castration-Resistant Prostate CancerChemotherapy-naive castration-resistant prostate cancer
JPRN-jRCT2080221877Takeda Pharmaceutical Company Limited72
进行中(未招募)
1 期
Study to find out the effects and fate of treatment with Orteronel plus prednisone in Japanese and non Japanese people that have not recieved cancer therapy for prostate cancer.progressive castration-resistant prostate cancer.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2012-001539-30-NLMillennium Pharmaceuticals, Inc.144
已完成
2 期
A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancercastrationresistant prostate cancer (mCRPC)chemotherapy-naïvemetastaticprogressiveprostate cancer1003859310036958
NL-OMON37312Millenium Pharmaceuticals8